PMID- 1371713
OWN - NLM
STAT- MEDLINE
DCOM- 19920409
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 69
IP  - 6
DP  - 1992 Mar 15
TI  - Tumor cell dissemination triggers an intrathecal immune response in neoplastic 
      meningitis.
PG  - 1475-80
AB  - The intrathecal immune response in neoplastic meningitis (NM) was studied by 
      quantitation of immune parameters such as immunoglobulin G (IgG); IgM; 
      interleukins (IL) 1, 2, 4, and 6; soluble IL-2 receptors (sIL-2R); interferon 
      gamma (IFNy); tumor necrosis factor-alpha (TNF alpha); and three tumor markers, 
      carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and fibronectin (FN), in 
      47 paired cerebrospinal fluid (CSF) and serum samples from patients with NM from 
      different carcinomas, malignant melanoma, and lymphoma. Elevated IgG and IgM 
      indices, CSF oligoclonal Ig bands, and CSF IL-6 indicated an intrathecal immune 
      activation in most patients with NM. Results for IL-1, IL-2, and IL-4 were always 
      negative. sIL-2R and IFNy were detected occasionally but not associated with 
      specific malignant neoplasms. CSF TNF alpha was detected only in NM from cases of 
      malignant melanoma. None of the immune parameters proved useful for the 
      differentiation of NM from autoimmune or inflammatory conditions. Immune 
      parameters were not correlated with tumor markers CEA, AFP, or FN. Results for 
      AFP were positive only in a case of glioblastoma. CEA was a useful and specific 
      diagnostic parameter in carcinomatous NM. CSF FN levels frequently were elevated 
      but are not specific for NM.
FAU - Weller, M
AU  - Weller M
AD  - Department of Neurology, University of Tubingen, Germany.
FAU - Stevens, A
AU  - Stevens A
FAU - Sommer, N
AU  - Sommer N
FAU - Schabet, M
AU  - Schabet M
FAU - Wietholter, H
AU  - Wietholter H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Fibronectins)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-2)
RN  - 0 (Interleukin-6)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (alpha-Fetoproteins)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Breast Neoplasms/immunology/pathology
MH  - Carcinoembryonic Antigen/analysis
MH  - Carcinoma/immunology/pathology
MH  - Fibronectins/analysis
MH  - Humans
MH  - Immunoglobulin G/analysis
MH  - Immunoglobulin M/analysis
MH  - Interferon-gamma/analysis
MH  - Interleukin-1/analysis
MH  - Interleukin-2/analysis
MH  - Interleukin-4/analysis
MH  - Interleukin-6/analysis
MH  - Lung Neoplasms/immunology/pathology
MH  - Lymphoma, Non-Hodgkin/immunology/pathology
MH  - Melanoma/immunology/pathology
MH  - Meningitis/blood/cerebrospinal fluid/*immunology
MH  - Neoplastic Cells, Circulating/*immunology
MH  - Receptors, Interleukin-2/analysis
MH  - Spine/*immunology
MH  - Tumor Necrosis Factor-alpha/analysis
MH  - alpha-Fetoproteins/analysis
EDAT- 1992/03/15 00:00
MHDA- 1992/03/15 00:01
CRDT- 1992/03/15 00:00
PHST- 1992/03/15 00:00 [pubmed]
PHST- 1992/03/15 00:01 [medline]
PHST- 1992/03/15 00:00 [entrez]
AID - 10.1002/1097-0142(19920315)69:6<1475::aid-cncr2820690627>3.0.co;2-d [doi]
PST - ppublish
SO  - Cancer. 1992 Mar 15;69(6):1475-80. doi: 
      10.1002/1097-0142(19920315)69:6<1475::aid-cncr2820690627>3.0.co;2-d.